UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
1.
Full Text
R.E. Rainer and others. August 16 (calendar day, Aug. 17), 1937. -- Ordered to be printed
1937, United States congressional serial set, Volume serial set no. 10081, 5
eBook
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 10, pp. 2197 - 2203
Nilotinib | Progression | ENESTnd | Imatinib | Chronic myeloid leukemia | Newly diagnosed | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Follow-Up Studies | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Pyrimidines - adverse effects | Piperazines - therapeutic use | Benzamides | Imatinib Mesylate | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Piperazines - adverse effects | Usage | Research | Drug therapy | Health aspects | Index Medicus
Journal Article
Book
Industrial marketing management, ISSN 0019-8501, 2007, Volume 36, Issue 5, pp. 651 - 661
Entrepreneurial orientation | Young firms | Business performance | Competitive aggressiveness | Innovativeness | Autonomy | Risk-taking | Proactiveness | Business & Economics | Social Sciences | Management | Business | Children | Growth | Entrepreneurship | Analysis | Studies | High tech industries | Entrepreneurs | Innovations | Business growth | Impact analysis
Journal Article
Leukemia, ISSN 0887-6924, 05/2016, Volume 30, Issue 5, pp. 1044 - 1054
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Follow-Up Studies | Risk Assessment | Imatinib Mesylate - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Pyrimidines - administration & dosage | Cholesterol - blood | Humans | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Treatment Outcome | Pyrimidines - pharmacology | Leukemia, Myeloid, Chronic-Phase - mortality | Imatinib Mesylate - administration & dosage | Blood Glucose - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Nilotinib | Chronic myeloid leukemia | Comparative analysis | Drug therapy | Index Medicus | Original
Journal Article
Ore geology reviews, ISSN 0169-1368, 01/2017, Volume 80, pp. 1135 - 1159
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 10/2001, Volume 44, Issue 22, pp. 3616 - 3621
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Oligonucleotides - chemistry | Ruthenium | Antineoplastic Agents - chemical synthesis | Humans | DNA Adducts - chemistry | Enzyme Inhibitors - pharmacology | Topoisomerase I Inhibitors | Crystallography, X-Ray | Structure-Activity Relationship | Antineoplastic Agents - chemistry | Enzyme Inhibitors - chemical synthesis | Organometallic Compounds - chemical synthesis | Enzyme Inhibitors - chemistry | Topoisomerase II Inhibitors | Organometallic Compounds - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Tumor Cells, Cultured | Organometallic Compounds - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Lithos, ISSN 0024-4937, 01/2019, Volume 324-325, pp. 584 - 608
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imatinib Mesylate - administration & dosage | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Philadelphia Chromosome - drug effects | Pyridazines - adverse effects | Imidazoles - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | Adolescent | Aged | Drug-Related Side Effects and Adverse Reactions - classification | Antimitotic agents | Clinical trials | Medical colleges | Product development | Research institutes | Antineoplastic agents | Analysis | Index Medicus | Life Sciences | Cancer | Medicin och hälsovetenskap
Journal Article
Journal of psychopharmacology (Oxford), ISSN 0269-8811, 8/2016, Volume 30, Issue 8, pp. 717 - 748
switching | cardiovascular disease | risk assessment | metformin | schizophrenia | interventions for weight gain | psychosis | lifestyle | smoking cessation | aripiprazole | guidelines | antipsychotic | Alcohol misuse | diabetes | dyslipidaemia | overweight | obesity | Neurosciences | Clinical Neurology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Neurosciences & Neurology | Psychiatry | Science & Technology | Cardiovascular Diseases - etiology | Psychotic Disorders - complications | Antipsychotic Agents - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Schizophrenia - complications | Antipsychotic Agents - administration & dosage | Overweight - therapy | Metabolic Diseases - therapy | Overweight - etiology | Metabolic Diseases - etiology | Obesity - therapy | Obesity - etiology | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Weight Gain | Complications and side effects | Care and treatment | Antipsychotic drugs | Primary health care | Alcoholism | Dosage and administration | Management | Cardiovascular diseases | Risk factors | Health care | Substance abuse treatment | Neuroleptics | Mental disorders | Body weight | Clinical trials | Schizophrenia | Cardiovascular disease | Alcohol | Guidelines | Psychosis | Psychotropic drugs | Drug tolerance | Medical research | Fasting | Life expectancy | Diabetes mellitus | Health risks | Risk analysis | Interfaces | Glucose tolerance | Reviews | Life span | Alcoholic beverages | Diabetes | Health risk assessment | Risk management | Smoking | Index Medicus
Journal Article